Drug Profile
Octocog alfa - Bayer
Alternative Names: Factor VIII - Bayer; Helixate; Kogenate; Recombinant factor VIII - BayerLatest Information Update: 23 Sep 2021
Price :
$50
*
At a glance
- Originator Ipsen
- Developer Bayer
- Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
- Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Market Withdrawal Haemophilia
Most Recent Events
- 19 Nov 2002 Bayer's research collaboration with PolyMASC (Valentis) has expired and Bayer has decided not to enter into any further agreement
- 19 Nov 2002 Bayer and PolyMASC have completed the feasibility study examining the use of PolyMASC's ProtoMASC technology for possible development of a chemically-modified factor VIII
- 10 Apr 2001 Withdrawn for Haemophilia in Canada (Parenteral)